Loading company…
Shenzhen Sinobio Biopharmaceutical develops recombinant botulinum toxin and related technologies.
Founded in 2024 and based in Shenzhen, China, Shenzhen Sinobio Biopharmaceutical researches and develops recombinant botulinum toxin. Its technologies include a synthetic biology preparation process, an AI protein design and directed evolution platform, and a high-throughput protein function screening platform. The company raised angel funding in May 2025.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in